Version May 2024
Anesthesia, ocular: Apply 2 drops to ocular surface in area where procedure will occur; may reapply to maintain effect.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Refer to adult dosing.
(For additional information see "Lidocaine (ophthalmic): Pediatric drug information")
Anesthesia, ocular: Ophthalmic gel: Children and Adolescents: Apply 2 drops to ocular surface in area where procedure to occur; may reapply to maintain effect.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.
Central Nervous System: Localized burning
Ophthalmic: Conjunctival hyperemia, diplopia, epithelial keratopathy, visual disturbance
There are no contraindications listed in the manufacturer's labeling.
Concerns related to adverse effects:
• Corneal ulceration: Prolonged use may cause permanent corneal ulceration and/or opacification with loss of vision.
Dosage form specific issues:
• Appropriate use: For ophthalmic use only; not for injection.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Gel, Ophthalmic, as hydrochloride [preservative free]:
Akten: 3.5% (1 mL)
No
Gel (Akten Ophthalmic)
3.5% (per mL): $28.03
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Ophthalmic: For topical ophthalmic use only; not for injection. For administration by health care provider; not for patient self-administration. For single use only; discard unused portion.
For topical ophthalmic use only; not for injection. For single use only; discard unused portion.
Anesthesia, ocular: To provide local anesthesia to ocular surface during ophthalmologic procedures.
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.
Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Risk C: Monitor therapy
Adverse events were not observed in animal reproduction studies. Although systemic exposure is not expected following application of the ophthalmic gel, cumulative exposure from all routes of administration should be considered.
When administered by injection for dental or obstetric analgesia, small amounts of lidocaine are detected in breast milk (Lebedevs 1993; Ortega 1999). Although systemic exposure is not expected following application of the ophthalmic gel, cumulative exposure from all routes of administration should be considered.
Local anesthetics block both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction.
Onset of action: 20 seconds to 5 minutes (median: 40 seconds)
Duration: 5 to 30 minutes (median: 15 minutes)
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
